TipRanks
Jinhai International Group Holdings Limited (HK:2225)
:2225
Hong Kong Market
Want to see HK:2225 full AI Analyst Report?

Jinhai International Group Holdings Limited (2225) AI Stock Analysis

1 Followers

Top Page

HK:2225

Jinhai International Group Holdings Limited

(2225)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - Gpt-5.6Sol)
Rating:44Neutral
Price Target:
HK$4.50
▲(262.90% Upside)
Action:Reiterated
Date:09/30/26
The score is primarily weighed down by weak financial performance: sharp margin compression, sustained net losses, and three years of negative operating/free cash flow. Technicals are mixed but lean weak in the near term (below 20/50-day averages with low RSI/Stoch). Valuation is also unattractive/unclear due to a very negative P/E and no provided dividend yield.
Positive Factors
Revenue Growth
The 17.5% increase in 2025 revenue indicates that the company is still expanding its topline despite broader profitability challenges. Continued revenue growth can support operating leverage and provide a larger base from which management may improve pricing, utilization, and cost efficiency over the next several quarters.
Negative Factors
Margin Compression and Sustained Losses
Sharp gross-margin compression alongside deep operating and net losses indicates that revenue growth is not translating into durable earnings. If weaker margins persist, the company may have limited capacity to absorb costs, reinvest in growth, or generate shareholder returns, making profitability recovery the central fundamental challenge.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The 17.5% increase in 2025 revenue indicates that the company is still expanding its topline despite broader profitability challenges. Continued revenue growth can support operating leverage and provide a larger base from which management may improve pricing, utilization, and cost efficiency over the next several quarters.
Read all positive factors

Jinhai International Group Holdings Limited (2225) vs. iShares MSCI Hong Kong ETF (EWH)

Jinhai International Group Holdings Limited Business Overview & Revenue Model

Company Description
Jinhai Medical Technology Ltd. specializes in offering workforce solutions and a range of complementary support services. Catering primarily to building and construction contractors, their comprehensive service portfolio encompasses dormitory mana...

Jinhai International Group Holdings Limited Financial Statement Overview

Summary
Despite revenue growth in 2025 (+17.5%), profitability has deteriorated sharply with materially lower gross margin and deep operating/net losses (2025 net margin ~-36.9%). Cash flow is also a key risk: operating and free cash flow have been negative for three consecutive years (2023–2025). The balance sheet leverage appears manageable (debt-to-equity <0.5), but consistently negative ROE highlights ongoing value destruction.
Income Statement
24
Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue66.07M46.28M50.24M45.64M22.28M21.90M
Gross Profit11.79M7.19M11.48M12.03M10.12M7.73M
EBITDA-4.75M-13.39M-15.07M1.11M5.25M5.44M
Net Income-11.23M-17.08M-17.96M-3.14M468.00K-246.21K
Balance Sheet
Total Assets100.24M88.83M58.87M62.22M40.27M33.77M
Cash, Cash Equivalents and Short-Term Investments29.25M36.78M14.93M26.76M23.95M25.91M
Total Debt14.20M14.91M14.52M10.08M4.45M1.87M
Total Liabilities44.58M36.87M26.09M24.73M15.68M9.75M
Stockholders Equity51.91M51.28M31.81M37.47M24.37M24.28M
Cash Flow
Free Cash Flow-8.57M-6.18M-4.26M-3.15M3.06M2.73M
Operating Cash Flow-5.62M-6.08M-3.25M-1.91M4.24M3.34M
Investing Cash Flow-9.56M3.47M-9.22M-6.51M-1.15M-2.64M
Financing Cash Flow27.17M26.68M2.93M13.62M-3.72M-4.81M

Jinhai International Group Holdings Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.24
Price Trends
50DMA
5.12
Negative
100DMA
4.31
Negative
200DMA
3.35
Positive
Market Momentum
MACD
-0.23
Positive
RSI
38.93
Neutral
STOCH
24.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2225, the sentiment is Negative. The current price of 1.24 is below the 20-day moving average (MA) of 5.35, below the 50-day MA of 5.12, and below the 200-day MA of 3.35, indicating a neutral trend. The MACD of -0.23 indicates Positive momentum. The RSI at 38.93 is Neutral, neither overbought nor oversold. The STOCH value of 24.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2225.

Jinhai International Group Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
HK$975.27M5.0715.17%37.66%6.09%21.21%
65
Neutral
HK$1.02B7.103.86%9.93%――
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
58
Neutral
HK$516.06M3.948.42%5.71%9.13%―
45
Neutral
HK$81.59M-2.76-43.31%29.46%――
44
Neutral
HK$22.58B-330.33-21.76%―75.36%49.21%
42
Neutral
HK$43.20M-19.58-1.42%―-14.98%-120.83%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2225
Jinhai International Group Holdings Limited
4.25
3.11
272.81%
HK:2180
ManpowerGroup Greater China Limited
4.70
-0.48
-9.32%
HK:6100
Tongdao Liepin Group
2.02
-0.99
-32.95%
HK:6919
Renrui Human Resources Technology Holdings Limited
3.33
-1.53
-31.51%
HK:8031
ETS Group Limited
0.23
0.04
21.05%
HK:8462
Omnibridge Holdings Ltd.
0.07
-0.02
-22.58%

Jinhai International Group Holdings Limited Corporate Events

Jinhai Medical Revamps Board and Committees with New Independent Director
Sep 18, 2026
Jinhai Medical Technology Limited has restructured its board, appointing finance and audit specialist Ms. Liu Jinjing as an independent non-executive director effective 18 September 2026. Her appointment brings over 15 years of professional experi...
Jinhai Medical Restructures Board and Committees to Bolster Governance
Sep 18, 2026
Jinhai Medical Technology Limited has updated the composition of its board of directors effective 18 September 2026, appointing Mr. Chen Guobao as chairman, Mr. Li Bin as co-chairman and Mr. Wang Zhenfei as chief executive officer, alongside non-e...
Jinhai Medical Clarifies Use of Listing and Placing Proceeds
Sep 14, 2026
Jinhai Medical Technology Limited issued a supplemental announcement to clarify how it has used and plans to use net proceeds from its listing and October 2023 placings up to 31 December 2025. The company detailed reallocations among acquiring a f...
Jinhai Medical Narrows Interim Loss as Revenue More Than Doubles
Aug 27, 2026
Jinhai Medical Technology Limited reported a sharp rise in revenue to S$34.0 million for the six months ended 30 June 2026, more than doubling from S$14.5 million a year earlier, driven by improved business performance. Despite higher cost of sale...
Jinhai Medical Technology Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 4, 2026
Jinhai Medical Technology Limited has scheduled a board meeting for 27 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The board will also consider the declaration of an interim dividend, indi...
Jinhai Medical Appoints Veteran CMO to Drive Minimally Invasive Growth
Aug 3, 2026
Jinhai Medical Technology Limited has appointed industry veteran Ma Chengdong as its chief marketing officer, effective 3 August 2026 for an initial one-year term, tasking him with leading marketing strategy, market access, academic promotion, sal...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 30, 2026